SOUTH SAN FRANCISCO, Calif. — Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, today announced the initiation of its Phase 1b proof-of-concept study of VRG50635 for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS). The study...
research News
AURORA, Colo.– Researchers at the University of Colorado Anschutz Medical Campus and collaborators across the country have conducted the largest and most diverse study of men with extra X or Y chromosomes in the US using a large dataset of military veterans. The results could lead to better diagnoses of...
SOUTH SAN FRANCISCO, Calif. — Vevo Therapeutics, a biotechnology company using its Mosaic technology and next generation AI to uncover better drugs for more patients, announced today that it has generated the world’s largest single-cell atlas of how drugs interact with and affect tumor cells. The company’s Mosaic platform is...
Barcelona, Spain – Published in Clinical Cancer Research, results of a preclinical study led by investigators of the Vall d’Hebron Institute of Oncology’s (VHIO) Stem Cells and Cancer Group, headed by Héctor G. Palmer, pave the way for systemic targeted therapy in patients with pseudomyxoma peritonei, a rare form of...
LEIDEN, Netherlands — Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases, today announced a $60 million (€54 million) Series B financing. The financing was led by new investor Ackermans & van Haaren (AvH) with existing co-leads Droia Ventures, EQT Life Sciences and Kurma Partners...
CAMBRIDGE, Mass. – Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced today the enrollment of the first subject in a natural history study dedicated to patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). ALSP is a rare, genetically...
BUFFALO, NY – A new research paper was published in Oncotarget’s Volume 15 on March 5, 2024, entitled, “GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells.” In this new study, researchers Laurence Booth, Jane L. Roberts, Cameron West, and Paul Dent from Virginia Commonwealth University and Genzada Pharmaceuticals...
Blacksburg, Virginia – A team of Virginia Tech researchers was awarded nearly $2 million from the National Institute of Diabetes and Digestive and Kidney Disease, part of the National Institutes of Health, to explore novel approaches for treating Type 2 diabetes and obesity. Type 2 diabetes affects more than 38.4...
Blacksburg, Virginia – Living organisms often create what is needed for life from scratch. For humans, this process means the creation of most essential compounds needed to survive. But not every living thing has this capability, such as the parasite that causes malaria, which affected an estimated 249 million people...
Blacksburg, VA – Cancer is the monster of our society. Last year alone, more than 600,000 people in the United States died from cancer, according to the American Cancer Society. The relentless pursuit of understanding this complex disease has shaped medical progress on developing treatment procedures that are less invasive...